On May 31, 2022 Pillar Biosciences, the leader in Decision Medicine, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, reported that its abstract, "Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp Technology", has been published online in the Journal of Clinical Oncology, in conjunction with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting (Press release, Pillar Biosciences, MAY 31, 2022, View Source [SID1234615283]). The company will also be showcasing its highly accurate and sensitive NGS genetic testing technology at booth #17157 June 4 through June 6, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"There is a critical need for NGS tests that can accurately and rapidly identify somatic variants in cancer patients. Current NGS tests can have high failure rates which delay the return of actionable results to physicians, significantly impacting time to diagnosis and critical treatment decisions," said Randy Pritchard, CEO of Pillar Biosciences. "The findings from our study underscore the accuracy and reliability of our SLIMamp technology and demonstrate its ability to generate highly accurate results from lower quality samples that have failed other NGS tests. We are pleased that this study has been published online and look forward to demonstrating the capabilities of our NGS genetic testing solutions at ASCO (Free ASCO Whitepaper)."
In the study, 48 tumor samples failing one or more pre-analytical quality control (QC) sample parameters for whole exome sequencing (WES) from an accredited diagnostic genomics laboratory were sequenced using Pillar Bioscience’s oncoReveal Solid Tumor Panel. Results demonstrated that the panel achieved high sequencing coverage (>3,000X) for all 48 samples and was able to generate clinical reports for 45 samples (94%). 38 of these reports (79%) contained clinically actionable or significant variants that would not have otherwise been identified with currently available panels. The study showed that oncoReveal Solid Tumor Panel with Pillar Biosciences’ proprietary SLIMamp technology, was able to generate reliable, interpretable results for almost all of the samples that had failed pre-analytical QC for WES.
At booth #17157, Pillar Biosciences will also be featuring the company’s extensive portfolio of NGS genetic testing solutions, including the oncoReveal Dx Lung and Colon Cancer Assay, PillarHS Multi-Cancer Panel, Essential MPN Panel, Multi-Cancer with CNV and RNA Fusion Panel, and Myeloid Panel.